Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.

[1]  T. Powles,et al.  Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO) , 2023, Journal of Clinical Oncology.

[2]  R. Motzer,et al.  Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Harrison,et al.  Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial , 2022, Journal for ImmunoTherapy of Cancer.

[4]  K. Yonemori,et al.  Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. , 2022, The New England journal of medicine.

[5]  J. Hsieh,et al.  A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. , 2021, European urology.

[6]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[7]  J. Larkin,et al.  Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Atkins,et al.  Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I. Thompson,et al.  A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial , 2021, The Lancet.

[10]  G. De Velasco,et al.  Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome , 2020, Modern Pathology.

[11]  S. Signoretti,et al.  Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma , 2020, JAMA oncology.

[12]  N. Rioux-Leclercq,et al.  Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. , 2020, European journal of cancer.

[13]  R. Motzer,et al.  Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Charles Swanton,et al.  Renal cell carcinoma , 2017, Nature Reviews Disease Primers.

[15]  C. Porta,et al.  Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. , 2016, European journal of cancer.

[16]  P. Tamboli,et al.  Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. , 2016, European urology.

[17]  J. Hainsworth,et al.  Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. , 2016, The Lancet. Oncology.

[18]  A. Ravaud,et al.  First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[20]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.